Galectin Therapeutics Inc. (GALT) Investor Relations Documents

Galectin Therapeutics Inc. (GALT) investor relations documents from the company's IR site: 2 presentations, 37 press releases; latest deck 2026-07-15. Read in-app with summaries. First-party data.

Corporate Presentation, July 2026: Galectin Therapeutics is developing belapectin for MASH cirrhosis, with a Phase 3 protocol submission expected in Q3 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-14Press releasePDF Version
2026-08-14Press releaseGalectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
2026-08-04Press releasePDF Version
2026-08-04Press releaseGalectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Shee
2026-07-15PresentationCorporate Presentation, July 2026
2026-06-23Press releasePDF Version
2026-06-23Press releaseGalectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and
2026-06-16Press releasePDF Version
2026-06-16Press releasePDF Version
2026-06-12Press releasePDF Version
2026-06-12Press releasePDF Version
2026-06-12Press releasePDF Version
2026-06-11Press releasePDF Version
2026-06-09Press releasePDF Version
2026-05-27Press releasePDF Version
2026-05-27Press releaseGalectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Dis
2026-05-15Press releasePDF Version
2026-05-15Press releaseGalectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
2026-05-11Press releasePDF Version
2026-05-11Press releaseGalectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatolo
2026-04-10Regulatory report9999999995-26-001150.pdf
2026-03-31Press releasePDF Version
2026-03-31Press releaseGalectin Therapeutics Reports 2025 Financial Results and Provides Business Update
2026-03-17Press releasePDF Version
2026-03-17Press releaseGalectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
2026-03-10PresentationKOL Event Presentation, March 2026
2026-02-26Press releasePDF Version
2026-02-26Press releaseGalectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dys
2025-04-15Press releasePDF Version
2025-03-31Press releaseGalectin Therapeutics Reports 2024 Financial Results and Provides Business Update
2024-11-14Press releasePDF Version
2024-11-14Press releaseGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
2024-08-13Press releaseGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
2024-05-15Press releasePDF Version
2024-05-15Press releaseGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
2024-03-29Press releaseGalectin Therapeutics Reports 2023 Financial Results and Provides Business Update
2023-11-13Press releaseGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
2023-08-14Press releaseGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update
2023-05-15Press releaseGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update
2023-03-30Press releaseGalectin Therapeutics Reports 2022 Financial Results and Provides Business Update

GALT overview · GALT earnings · GALT financials · GALT KPIs · GALT ownership · GALT peers · GALT filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.